Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Bought by International Assets Investment Management LLC

International Assets Investment Management LLC lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 248,773.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 104,527 shares of the company’s stock after acquiring an additional 104,485 shares during the quarter. International Assets Investment Management LLC owned about 0.34% of Medpace worth $32,041,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Schulhoff & Co. Inc. increased its position in shares of Medpace by 2.0% during the 3rd quarter. Schulhoff & Co. Inc. now owns 2,250 shares of the company’s stock valued at $545,000 after purchasing an additional 45 shares during the period. Campbell Newman Asset Management Inc. raised its position in Medpace by 0.4% in the fourth quarter. Campbell Newman Asset Management Inc. now owns 11,095 shares of the company’s stock worth $3,401,000 after acquiring an additional 46 shares in the last quarter. Treasurer of the State of North Carolina lifted its holdings in Medpace by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 10,230 shares of the company’s stock valued at $2,477,000 after acquiring an additional 50 shares during the last quarter. Sectoral Asset Management Inc. boosted its position in shares of Medpace by 4.9% during the 3rd quarter. Sectoral Asset Management Inc. now owns 1,181 shares of the company’s stock valued at $286,000 after purchasing an additional 55 shares in the last quarter. Finally, Front Row Advisors LLC lifted its stake in Medpace by 0.5% during the third quarter. Front Row Advisors LLC now owns 10,921 shares of the company’s stock valued at $2,644,000 after purchasing an additional 55 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on MEDP shares. Guggenheim upped their price target on Medpace from $453.00 to $464.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research note on Tuesday, April 23rd. UBS Group upgraded shares of Medpace from a “neutral” rating to a “buy” rating and boosted their price target for the company from $282.00 to $452.00 in a report on Thursday, February 15th. Finally, Robert W. Baird raised their target price on Medpace from $446.00 to $454.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 24th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Moderate Buy” and an average price target of $443.00.

Insider Activity

In related news, CEO August J. Troendle sold 15,102 shares of the company’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $400.69, for a total value of $6,051,220.38. Following the completion of the sale, the chief executive officer now directly owns 791,541 shares in the company, valued at $317,162,563.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO August J. Troendle sold 100,000 shares of Medpace stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $412.98, for a total value of $41,298,000.00. Following the transaction, the chief executive officer now owns 4,833,019 shares of the company’s stock, valued at $1,995,940,186.62. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO August J. Troendle sold 15,102 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $400.69, for a total transaction of $6,051,220.38. Following the completion of the sale, the chief executive officer now owns 791,541 shares of the company’s stock, valued at $317,162,563.29. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 204,442 shares of company stock worth $82,702,867. 20.30% of the stock is owned by corporate insiders.

Medpace Stock Performance

Medpace stock opened at $392.57 on Friday. The firm’s 50 day moving average price is $398.08 and its two-hundred day moving average price is $330.45. The firm has a market cap of $12.16 billion, a PE ratio of 40.02, a P/E/G ratio of 1.98 and a beta of 1.40. Medpace Holdings, Inc. has a twelve month low of $197.39 and a twelve month high of $421.00.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.75. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business’s revenue was up 17.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.27 EPS. Equities analysts anticipate that Medpace Holdings, Inc. will post 11.23 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.